Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20746624 | 0.86 | L3MBTL1 (0.38) | L3MBTL1MAPT | |
| SCHEMBL10820248 | 0.82 | L3MBTL1 (0.40) | L3MBTL1MAPT | |
| SCHEMBL24004413 | 0.79 | L3MBTL1 (0.53) | L3MBTL1MAPT | |
| SCHEMBL24004411 | 0.79 | L3MBTL1 (0.53) | L3MBTL1MAPT | |
| SCHEMBL13034058 | 0.79 | L3MBTL1 (0.53) | L3MBTL1MAPT | |
| SCHEMBL17811737 | 0.79 | AMY1A (0.41) | L3MBTL1MAPT | |
| SCHEMBL21565006 | 0.78 | L3MBTL1 (0.46) | L3MBTL1MAPT | |
| SCHEMBL27055134 | 0.77 | L3MBTL1 (0.39) | L3MBTL1MAPT | |
| SCHEMBL19790925 | 0.77 | L3MBTL1 (0.36) | L3MBTL1MAPT | |
| SCHEMBL19860207 | 0.77 | L3MBTL1 (0.36) | L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11026965-B2 | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190343869-A1 | NITRIC OXIDE-RELEASING CYCLODEXTRINS AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND METHODS PERTAINING THERETO | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343869-A1 | NITRIC OXIDE-RELEASING CYCLODEXTRINS AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND METHODS PERTAINING THERETO | NOS1, NOS2, NOS3 | L3MBTL1 3969/4885MAPT 2791/4885 |
| US-11026965-B2 | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto | NOS1, NOS2, NOS3 | L3MBTL1 3969/4885MAPT 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.